Equiduct Expands into the Swiss Market
Equiduct, the leading pan-European retail-focused exchange, today announced the launch of its Swiss equity segment, providing retail brokers using Apex with access to 138 of the most liquid Swiss-listed stocks — all priced in Swiss francs (CHF). The newly available securities include heavily traded household names such as Nestlé S.A., Novartis AG, UBS Group AG, and ABB Ltd.
Liquidity on the Swiss segment of Equiduct is supported by Apex market makers Virtu Financial, Hudson River Trading, and Optiver. As with all executions on Equiduct, trades on the Swiss segment will benefit from fully interoperable clearing via Equiduct’s pan-European network of CCPs: LCH Ltd, Cboe Clear, and the local Swiss CCP SIX x-clear.
This expansion follows formal approval from the Swiss Financial Market Supervisory Authority (FINMA), which recognises Börse Berlin and Equiduct as a regulated market under Article 41 of FinfraG. This status also paves the way for Swiss banks and brokers to join Equiduct as direct exchange members, further enhancing best-execution capabilities for Swiss retail brokers and benefiting the Swiss retail investment community.
To support the launch of the Swiss segment and Equiduct’s growth in the region, the responsibilities of Massimo Formichi Moglia, Head of Italy, have been expanded to include Switzerland — ensuring continuity and leveraging regional synergies.
Wail Azizi, Chief Strategy Officer at Equiduct, said: “Our Swiss expansion, backed by formal recognition from FINMA, marks a significant milestone in Equiduct’s mission to deliver true pan-European best execution for retail investors and enables us to bring our market-leading, commission-free trading model to one of Europe’s most sophisticated markets. By adding Swiss equities to Equiduct, we’re also continuing to empower European retail brokers and their clients with broader access, greater transparency, and exceptional execution quality.”
With the launch of the Swiss market segment, Equiduct now offers commission-free best execution and consolidated market data products for over 1,873 stocks and ETFs across 13 European markets and 18 headline indices.
Notes to editors
About Equiduct
Equiduct is the leading pan-European retail-focused exchange built around the specific needs of the retail community.
Equiduct enables retail brokers to achieve Best Execution in Europe’s most liquid equities and ETFs across 13 European markets and provides high-quality cost-effective market data and insight products for both the retail community and institutional clients alike.
A market segment of Börse Berlin, Equiduct operates under Article 44 of MiFID II. In 2024, Equiduct reported 35 active retail brokers, 15.2 million trades executed, and a turnover of €85 billion.
For more information, visit www.equiduct.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250514652400/en/
Contacts
For further information, please contact:
Massimo Formichi Moglia, Country Head | Italy & Switzerland
Tel: +39 02 12 412 7314
Email: massimo.formichi@equiduct.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces FDA Approval of Zynyz ® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States15.5.2025 21:30:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz® (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). In addition, the FDA granted approval for Zynyz as a single agent for the treatment of adult patients with locally recurrent or with metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508024371/en/ Zynyz logo "The FDA approval of Zynyz marks a pivotal moment, bringing effective combination and monotherapy treatment options to patients with advanced anal cancer after decades of limited innovation," said Hervé Hoppenot,
DDC Announces Record 2024 Growth and Strategic Bitcoin Reserve Initiative in Shareholder Letter by Founder & CEO Norma Chu15.5.2025 21:23:00 EEST | Press release
DDC Enterprise Ltd. (NYSEAM: DDC), today released its 2024 full year results alongside a Shareholder Letter from Founder, Chairwoman, and CEO Norma Chu, underscoring the company’s positive financial performance and unveiling a pioneering Bitcoin accumulation strategy poised to redefine long-term value creation. To Our Valued Shareholders, 2024 was a year of transformative growth and strategic milestones for DDC. I am thrilled to share that we not only met our financial forecasts but exceeded expectations, delivering strong performance across key metrics while laying the groundwork for an even more exciting future. As we enter 2025, our momentum is accelerating, driven by disciplined execution and a bold new chapter in our corporate strategy. 2024 Financial & Operational Highlights Revenue Growth: USD 37.4 million, a 33% year-over-year increase, propelled by the strategic acquisition of U.S. brands and sustained resilience in our core China operations. Margin Expansion: Gross profit mar
Ras Al Khaimah’s Strong Economic and Investment Environment Validated by Fitch Affirmation of ‘A+’ Credit Rating, With Stable Outlook15.5.2025 21:18:00 EEST | Press release
Ras Al Khaimah’s strategic approach to sustainable, cross-sector growth and strong economic and investment environment has been validated by international credit rating agency Fitch, which reaffirmed the rating at ‘A+’ with a stable outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515907689/en/ Ras Al Khaimah’s strong economic and investment environment validated by Fitch affirmation of ‘A+’ credit rating, with Stable Outlook (Photo: AETOSWire) Ras Al Khaimah Government welcomed the announcement as an endorsement of the Emirate’s resilient and expanding economy, sound fiscal management and the clear vision and unwavering commitment of its leadership to sustainable, long-term development and growth. The Emirate’s landmark tourism projects, including a major integrated resort, luxury hotels and world-class leisure facilities, combined with a surge in real estate revenue, are creating opportunities for investors, driv
Cessna Citation CJ4 Gen3 Flight Test Program Advances Through Milestones as Second Test Article Takes Flight15.5.2025 21:00:00 EEST | Press release
Textron Aviation today announced a major program milestone for the Cessna Citation CJ4 Gen3 flight test program with the successful first flight of a second test article — P1. Testing on the P1 aircraft will focus on avionics, human factors and interiors. The Citation CJ4 Gen3 business jet is designed to keep pilots a step ahead in the cockpit by offering the next-generation Garmin G3000 PRIME avionics along with the most standard features in its class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515438856/en/ Cessna Citation CJ4 Gen3 flight test program advances through milestones as second test article takes flight. (Photo Credit: Textron Aviation) The Cessna Citation CJ4 Gen3 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. “This achievement continues the forward momentum of the CJ4 Gen3 program and reflects the dedication and expertise of our team in designing, certifying an
Aksia Welcomes Sebastiaan van den Berg, Christopher Schelling, and Benjamin Parks15.5.2025 17:00:00 EEST | Press release
Aksia is pleased to announce the addition of three distinguished professionals to our team: Sebastiaan van den Berg, Christopher Schelling, and Benjamin Parks. Their extensive experience and expertise will further strengthen Aksia's capabilities and commitment to delivering exceptional service to our clients. Sebastiaan van den Berg joins Aksia as a Partner on the Private Equity team. Sebastiaan will work closely with Aksia’s Pan-Alts and Private Equity teams to support the Firm’s EMEA clients’ Private Equity programs. With over 25 years of experience in global private equity, Sebastiaan brings a wealth of knowledge in portfolio management, investment underwriting, deal sourcing, and the private equity ecosystem. Most recently, Sebastiaan served as Partner, Co-Head GP Equity Solutions at Astorg. Christopher Schelling joins Aksia as a Managing Director on the Pan-Alts team. Chris will be working with Aksia’s data, risk and asset class teams on research projects that benefit Aksia’s clie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom